VivoSeq
Hematology

Hematopoietic Stem Cell Transplant

0

Pipeline Programs↗

9

Active Trials↗

4

Companies Involved↗

Hematopoietic Stem Cell Transplant is an early-stage landscape with 0 programs across 4 companies. The most active players are Pfizer, Astellas, Incyte.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalIncyte logo

Incyte

0 programs

PreclinicalV

Vor Biopharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

40

clinical trials

Completed16 · 40%
Unknown status6 · 15%
Terminated6 · 15%
Recruiting5 · 13%
Active, not recruiting3 · 8%
Withdrawn2 · 5%
Other2 · 5%

Clinical Trials

Trial Activity

40 trials

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Recruiting·OOmeros Corporation·Phase 2·NCT05855083·18 enrolled
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Recruiting·—·Phase 2·NCT05796570·37 enrolled
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04339777·66 enrolled
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Recruiting·—·Phase 2·NCT06059391·216 enrolled
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Recruiting·BBlueSphere Bio, Inc·Phase 1/2·NCT06704152·38 enrolled
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
Active, not recruiting·—·Phase 2·NCT04908735·7 enrolled
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
Active, not recruiting·—·Phase 1·NCT03922035·36 enrolled
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled
Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability
Not yet recruiting·MMayo Clinic·Preclinical·NCT07595146·100 enrolled
A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant
Completed·Astellas logoAstellas·Phase 1·NCT00606268·42 enrolled
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Completed·Pfizer logoPfizer·Phase 3·NCT00289991·489 enrolled
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01626092·3 enrolled
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Completed·UUNC Lineberger Comprehensive Cancer Center·N/A·NCT04645667·38 enrolled
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed·UUniversity of California, San Francisco·N/A·NCT03609827·25 enrolled
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
Completed·UUniversity of Chicago·Phase 2·NCT03030989·50 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)